Objective: To study the effect of bacteriophage treatment on highly virulent extraintestinal Escherichia coli pneumonia in mice and compare it with conventional antimicrobial treatment. Design: Animal investigation. Setting: University research laboratory. Subjects: Pathogen-free 8-week-old Balb/cJRj male mice. Interventions: Two bacteriophages (536_P1 and 536_P7) were isolated from sewage using strain 536, a highly virulent extraintestinal E. coli. Their in vitro and in vivo efficacy against strain 536 and a ventilator-associated pneumonia E. coli were tested. The first group of mice were infected by intranasal instillation of bioluminescent strain 536 and received 536_P1 intranasally, cef-triaxone, or control. The second group of mice was infected with the ventilator-associated pneumonia strain and received 536_P7. Adaptation of 536_P7 to this clinical isolate was also evaluated in vitro and in vivo. Measurements and Main Results: In vivo efficacy of bacteriophage and antibiotic treatment were assessed by recording bioluminescence for short-time periods and by recording body weight and survival of mice for longer periods. Both treatments improved survival compared with control (100% vs 0%), and in vivo bioluminescence recordings showed a similar rapid decrease of emitted light, suggesting prompt bacterial clearance. The majority of mice infected by the ventilator-associated pneumonia strain were not rescued by treatment with 536_P7; however, in vitro adaptation of this bacteriophage toward the ventilator-associated pneumonia strain led to isolate a variant which significantly improved in vivo treatment efficacy (animal survival increased from 20% to 75%). Conclusions: Bacteriophage treatment was as effective as antibiotherapy to provide 100% survival rate in a lethal model of highly virulent E. coli pneumonia. Adaptation of a bacteriophage is a rapid solution to improve its efficacy toward specific strains. These results suggest that phage therapy could be a promising therapeutic strategy for ventilator-associated pneumonia. (Crit Care Med 2015; 43:e190-e198) 
L ower respiratory tract infections (i.e., pneumonia) represent the third leading cause of mortality in the world according to the World Health Organization epidemiological data center (1) and the most frequent life-threatening nosocomial infection in the ICU. All patients undergoing invasive mechanical ventilation are indeed exposed to a timedependent risk of ventilator-associated pneumonia (VAP). VAP is associated with an impaired prognosis and an increase in costs and probably also in mortality although recent studies have considerably lowered VAP attributable mortality (2) (3) (4) (5) . Two main factors directly impact treatment's efficacy of these infections and patients' outcome: bacterial virulence and Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's website (http://journals.lww.com/ ccmjournal).
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Treatment of Highly Virulent Extraintestinal Pathogenic
Escherichia coli Pneumonia With Bacteriophages* antibiotic resistance. In the United States, at least 23,000 death are directly linked to antibiotic-resistant infections, and the highest mortality is attributed to Enterobacteriaceae (mainly Klebsiella species and Escherichia coli) (6) .
In western countries, E. coli is responsible for ICU infections as often as Pseudomonas (2, 7) . Recently, Enterobacteriaceae were found more frequently than Pseudomonas aeruginosa in microbiologically documented VAP (8) , E. coli being one of the most prevalent of them.
In the ICU setting, E. coli strains involved in VAP belong predominantly to the B2 phylogenetic group and possess a high number of virulence factors (9) . Interestingly, a number of these strains belonged to subgroup III (sequence type 127), including the highly virulent archetypal strain 536 (10) . Finally, E. coli is well known to develop antibiotic resistance (11) and is then emerging as one of the greatest microbiological threat to come, urging the development of specific antibacterial treatments (12, 13) , especially in the ICU setting.
In this context, bacteriophages may offer an interesting perspective and recent calls have been made to promote their use (14) (15) (16) . Bacteriophages are viruses that infect specifically bacterial cells. They are unique among antibacterial agents in their ability to increase their number in presence of the bacterial target. During the last decade, a renewed interest for phage therapy has led to publication of several encouraging in vitro and in vivo studies (17) (18) (19) (20) . Several clinical trials (http://clinicaltrials.gov) have been initiated, and the European Union has recently funded a large randomized controlled trial to test the efficacy of phage therapy to treat infected burn wounds (http:// www.phagoburn.eu).
In this article, we investigated the use of bacteriophages to treat pneumonia induced by highly virulent extraintestinal pathogenic E. coli. Using in vivo kinetics assessed by bioluminescence recording, we showed that phage therapy is as effective as antibiotics. Additional observations demonstrate the flexibility of bacteriophage adaptation, which represents a rapid and easy way to improve bacteriophage efficacy toward clinical strains.
MATERIAL AND METHODS

E. coli Strains
Both strains, E. coli 536 (10) and PDP302, belong to the B2 phylogenetic group of highly virulent extraintestinal E. coli, determined by the triplex polymerase chain reaction technique (21) . Strain PDP302 was isolated from an ICU patient under mechanical ventilation in whom VAP developed and belongs to a well-characterized collection (9) .
The 536-lux strain was obtained by transformation of the wild-type 536 strain with plasmid pCM17. pCM17 carries the kanamycin-resistance gene and the luxCDABE operon from Photorhabdus luminescens under OmpC promoter for a constitutive expression (22, 23) . Stability over time of the light-emitting phenotype without antibiotic pressure has been checked by means of repeated seeding of liquid cultures over 10 days. Quantification and analysis of luminescence, both on liquid and solid medium, showed that the light produced started to decrease only after the 7th day of intense growth conditions (supplemental data, pages 1 and 2, Supplemental Digital Content 1, http:// links.lww.com/CCM/B242).
Bacteriophages Isolation, Preparation, Adaptation, and Sequencing
Bacteriophages 536_P1 and 536_P7 were isolated from sewage using strain 536 as previously described (20, 24) .
In vitro activity of a given bacteriophage on a nonhost strain was assessed by its efficiency of plaquing (EOP). The term "nonhost strain" refers to a strain which was not the one used to isolate the bacteriophage. EOP was calculated as the ratio of number of plaques formed by the bacteriophage on the nonhost strain to the number of plaques formed on its host, using the same bacteriophage solution (supplemental data, pages 2 and 3, Supplemental Digital Content 1, http://links. lww.com/CCM/B242).
Bacteriophage 536_P1 and 536_P7 displayed an EOP of 1 on 536-lux strain (compared with wild-type 536). Bacteriophage 536_P7 displayed an EOP of 1 on strain PDP302 (supplemental data, Supplemental Digital Content 1, http://links.lww.com/CCM/ B242). Heat-inactivated 536_P1 was obtained after incubation at 80°C for 10 minutes (total loss of infectivity was then confirmed by titration).
We adapted bacteriophage 536_P7 to strain PDP302 to improve its virulence against this strain. It is indeed known, since the pioneered study by d'Herelle (25) in 1917, that the amplification of bacteriophages on a bacterial strain different (but close enough) to the original host (initially used to isolate them) can lead to select bacteriophage variants that could display increased infectivity toward this different strain. The in vitro adaptation of bacteriophage 536_P7 to strain PDP302 was performed as follows: a liquid culture of strain PDP302 (50 mL, in Lysogenic broth) was infected by bacteriophage 536_P7 at multiplicity of infection (MOI) of 10 -3 (i.e., a ratio of virus to bacteria equal to 0.001) for 3 hours. Then, 5 mL was centrifuged 5 minutes at 8,000 g and the supernatant was sterilized by filtration. A fraction of this lysate was titrated on both parental (536) and targeted (PDP302) strains before infecting a new 50 mL PDP302 liquid culture. These steps were repeated four times ending with plaque isolation (24) to purify the adapted bacteriophage, called 536_ P7_PDP302. Kinetics of lysis of strain PDP302 by bacteriophages 536_P7 and 536_P7_ PDP302 were performed in a 96-well plate (supplemental data, page 3, Supplemental Digital Content 1, http://links.lww.com/CCM/B242).
All bacteriophages solutions were purified as described previously using cesium chloride gradient ultracentrifugation (26) . Transmission electron microscopy observations were performed following uranyl acetate staining (photographs of bacteriophages 536_P1 and 536_P7 are shown in the supplemental data (page 4, Supplemental Digital Content 1, http:// links.lww.com/CCM/B242).
Sequencing of bacteriophage 536_P1 and 536_P7 was performed using Illumina sequencing technology (Illumina, Inc., San Diego, CA). DNA was extracted from lysates, using a DNase and RNase pretreatment followed by a phenol-chloroform extraction method, modified from Pickard (27) . Genome of 536_P1 (149,471 bp) was found 99% identical on 90% of its length to phAPEC8 bacteriophage (28) . Genome of 536_P7 (148,442 bp) was found 98% identical on 93% of its length to phi92 bacteriophage (29) .
Animals and Ethics Statement
Eight-week-old BALB/cJRj male mice (Janvier, Le Genest Saint Isle, France) were housed in animal facility in accordance with French and European regulations on the care and protection of laboratory animals. Protocols were approved by the veterinary staff of the Institut Pasteur animal facility (approval number 10.565) and the National Ethics Committee regulating animal experimentation (approval number 2012-0018). Intraperitoneal administration of 1.25 μg (50 μg/kg) of buprenorphine (Buprecare; AST Farma, Oudewater, The Netherlands) was systematically performed on all mice at 8 and 24 hours post infection to limit pain and dyspnea. Food and drink were provided ad libitum.
Animal Infection and Treatment, Bioluminescence Recording
Mice, anesthetized with a mixture of ketamine and xylazine administered via intramuscular route, were infected intranasally with 1 × 10 7 (non-100% lethal dose) or 4 × 10 7 colony-forming unit (CFU) (100% lethal dose) of 536-lux strain or by 1.5 × 10 7 CFU (non-100% lethal dose) of PDP302 strain and resuspended in 20 μL of phosphate-buffered saline (PBS). Two hours later, mice were anesthetized by isoflurane inhalation (2%) or by a second intramuscular injection of ketamine/xylazine. Mice then received a second 20 μL intranasal administration of PBS (control group) or 20 μL of the therapeutic bacteriophage solution (in PBS) with a MOI of 0.3, 3, or 10. Mice were weighed daily (and euthanized if weight loss was > 25%, a limit never reached in the present experiments) and visited twice daily to assess behavior and mortality for at least 14 days. Ceftriaxone sodium (TEVA, Paris, France) was suspended in normal saline. A 50 mg/kg dose (1,250 μg, 200 μL) was injected intraperitoneally 2 hours post infection and every 12 hours during 2 days (i.e., a total of five injections). In parallel, control group received 200 μL injections of normal saline. Ceftriaxone minimal inhibitory concentration for the 536-lux strain was inferior to 0.03 mg/L (according to standardized disk diffusion method).
Photon emission of the luminescent bacteria was recorded and analyzed as previously described (20) using an Ivis Spectrum imaging system (PerkinElmer, Richmond, CA) and a dedicated software (Living Image; PerkinElmer). Amount of photon emitted was expressed as photon/s/cm 2 /steradian and normalized by subtracting the background luminescence noise using a noninfected control mouse included in each recording. A typical recording is shown in Figure 1 .
Bacteriophage and Bacterial Counts in Lung Homogenate, Analysis of Bronchoalveolar Lavage Fluids
These analyses were performed independently from experiments assessing mortality and bioluminescence signal, using four mice per condition and per time point. Lungs were removed from euthanized mice at 2, 6, and 16 hours post infection, weighed, and mechanically homogenized (Ultra-Turrax; IKA, Staufen, Germany) before being serially diluted to count colony of strain 536 on agar plate containing kanamycin (triplicate) and count plaques of bacteriophage 536-P1 on agar plates covered with strain 536 (triplicate).
Bronchoalveolar lavage (BAL) procedure and processing of BAL fluids for cytological (cell counts and microscopic observations) and biochemical analysis (total proteins, lactate dehydrogenase, and keratinocyte-derived cytokine [KC] levels) were performed as detailed in the supplemental data (page 4, Supplemental Digital Content 1, http://links. lww.com/CCM/B242).
Statistical Analysis
All statistical analyses were performed by using GraphPad Prism version 5.00 (Graph-Pad Software, La Jolla, CA Fig. 2A) . Luminescence quantification of the mice lung area revealed that the amount of light emitted was not different within the first 4 hours post infection but became significantly lower in the bacteriophage-treated mice as early as 6 hours post infection (i.e., 4 hr after the beginning of treatment; 5.0 × 10 3 [1.5 × 10 3 ; 6.7 × 10 3 ] vs 2.0 × 10 4 [1.6 × 10 4 ; 3.1 × 10 4 ] photon/s/cm 2 /steradian; p < 0.005) ( Fig. 3A) .
Microbiological and Cytological Analysis of Lung Homogenates and BAL Fluids
In a second set of two independent experiments, we quantified levels of bacteria, bacteriophages, cytokines, and cell markers in both PBS and bacteriophage-treated mice at 6 and 16 hours after initiating lung infection ( Table 1) . Bacterial counts were lower in the 536_P1-treated group than in the control group, reaching a difference greater than 2 Log 10 . Given that bacteriophages cannot increase without bacterial lysis, bacteriophage counts were also in agreement with these data, and we observed an increase of the viral population of 1.1 Log 10 between 6 and 16 hours post infection. In addition, the proportion of polymorphonuclears and the level of chemokine KC (C-X-C motif ligand [CXCL]-1) were reduced in the bacteriophage-treated group 16 hours post infection (Table 1 ). We also observed that BAL fluids from 536_P1-treated mice contained very few images of engulfed bacteria within polymorphonuclears or monocyte-macrophages compared with control mice (Table 1 ; see also representative pictures in supplemental data, pages 5-7, Supplemental Digital Content 1, http://links.lww.com/CCM/B242).
Total protein counts did not differ between treated and control mice. There was a trend toward lower levels of lactate dehydrogenase in the 536_P1-treated group (p = 0.10).
Comparison of E. coli 536-Lux Pneumonia Treatment With Either Bacteriophage 536_P1 or Ceftriaxone
In a third set of two independent experiments, all mice (n = 28) were challenged with a higher inoculum (4 × 10 7 CFU of E. coli 536-lux) leading to 100% lethal infection. Only treated mice were alive at day 3 and exhibited a greater weight loss (-18.5% ± 0.8%; p < 0.001) than during the set of experiment performed with a 1 × 10 7 CFU inoculum. Despite this, they presented the same recovery pattern (supplemental digital content, SDC page 5, Supplemental Digital Content 1, http:// links.lww.com/CCM/B242). Mortality at day 3 was 100% in the control group (n = 14) ( Fig. 2B) . Survival was 100% in both bacteriophage-treated mice (n = 8, MOI of 3) and ceftriaxone-treated mice (n = 6). Within the first 48 hours post infection, quantification of light emitted from lungs revealed that bacteriophage 536_P1 and ceftriaxone-treated groups led to an identical decrease of the signal, whether it be in terms of kinetic (slope) or raw values (Fig. 3B) . 
In Vitro Adaptation of Bacteriophages 536_P7 Is Required to Reach Efficient Pneumonia Treatment
Next, we searched for an E. coli VAP strain displaying equivalent characteristic to the archetypal strain 536 and identified strain PDP302 from our collection (9) . In vitro, this clinical strain was as efficiently infected by bacteriophage 536_P7 as strain 536 (EOP of 1; Material and Methods section) (supplemental digital content, Supplemental Digital Content 1, http://links. lww.com/CCM/B242). Once infected with PDP302 (1.5 × 10 7 CFU), untreated mice (PBS, n = 9) and those treated with bacteriophage 536_P7 (n = 10, MOI of 10) displayed, respectively, 88% and 80% mortality rate (two independent experiments). We then hypothesized that serial in vitro passages of 536_P7 bacteriophage on strain PDP302 could improve its in vivo infectivity toward this strain.
Treatment with 536_P7_PDP302, the resulting adapted bacteriophage isolated after five serial passages (Material and Methods section), was associated with a significant increase in survival (75%, p = 0.001, n = 8, MOI of 10) (Fig. 4) . Although agar plate assays were not able to differentiate 536_P7 and 536_P7_PDP302 bacteriophages (no gain in EOP), the in vivo improvement observed was in agreement with data obtained from lysis kinetics assays ( Fig. 5; supplemental 
DISCUSSION
In this study, we showed for the first time that experimental E. coli pneumonia was efficiently treated by bacteriophages. Its main results can be summarized as follows: 1) bacteriophage treatment enabled 100% survival of mice lethally infected with highly virulent extraintestinal E. coli strain 536; 2) it was associated with a significant decrease in lung inflammation; 3) it appeared to be as effective as ceftriaxone antibiotic treatment reaching 100% survival; 4) it decreased bacterial load in the lungs in a comparable manner as ceftriaxone treatment; and 5) in vivo bacteriophages efficacy could be rapidly enhanced by in vitro adaptation toward the targeted strain.
In this study, we focused on E. coli for the following reasons: 1) oropharyngeal colonization with Enterobacteriaceae has been long known as the first step toward Gram-negative bacteria VAP (30, 31); 2) recent data suggest that Enterobacteriaceae (including E. coli) are increasingly responsible for VAP, ahead of P. aeruginosa and Staphylococcus aureus (8, 32) ; and 3) Enterobacteriaceae in general and E. coli in particular represent the major threat in terms of antimicrobial resistance, including VAP (33) . We recently reported that E. coli strains infecting ICU patients closely resembled the highly virulent archetypal ExPEC strain 536 in terms of phylogenetic grouping, virulence factors, genes content, and in vivo virulence (9, 10) . To complete this proof of concept study, we reasoned it was necessary to also assess the efficacy of bacteriophage on strain PDP302, a clinical strain responsible for a VAP in an ICU patient. Strain PDP302 was one of the infrequent strain (10 tested) to be pathogenic for mice in our lung infection model, and interestingly, this strain turned out to share the same sequence type (ST127) as strain 536 (i.e., same clonal complex, ST127 being one of the most prominent sequence type within ExPEC). This observation fully illustrates the correlation that exists between sequence type and pathogenicity (34) .
The observed therapeutic effect was due to rapid bacterial clearance, as suggested by the rapid decrease in bioluminescence signal in the lungs (Fig. 3) and confirmed by direct www.ccmjournal.org e195 bacterial count 6 hours post infection. Next, we compared, for the first time in such model, efficacy of bacteriophage treatment to conventional antibiotherapy. Both treatments displayed striking resemblance in terms of kinetics ( Fig. 3B ) and both rescued 100% of lethally infected animals. In this regard, it should also be noted that we deliberately used a high-dose ceftriaxone treatment (100 mg/kg/d with repeated administrations), a molecule to which E. coli 536 is highly sensitive (minimum inhibitory concentration < 0.03 mg/L) to ensure maximum efficacy of the antimicrobial treatment and to avoid any bias in favor of the bacteriophage-treated group. We also observed that 16 hours after infection, bacteriophage-treated mice displayed less lung inflammation compared with untreated mice based on KC (CXCL-1) cytokine level. These data corroborated with cytological observations since phagocytic cells present in BAL fluids were virtually free of intracellular bacteria in bacteriophagetreated mice. We also found an increased number of monocytes-macrophages in BAL fluids of bacteriophage-treated mice 16 hours post infection (that we interpreted as the beginning of a resolution phase), but we did not perform phenotype analysis to check the precise part of resident cells (i.e., alveolar macrophages) and recruited ones (i.e., monocytes). Indeed, the latter could promote specific changes in local inflammatory balance (35) . However, in our case, given the minimal increase observed, even if statistically significant, the physiological relevance could be weak at this time point. In this study, we observed in vitro/in vivo bacteriophages efficacy discrepancies. These disparities that have been described a long time ago with antibiotics (36) have also, although more recently, been reported with bacteriophages (37, 38) . However, in striking contrast to antibiotic optimization that requires months if not years of research, bacteriophages can evolve very quickly (hours to days) enabling them to eventually adapt to a given targeted bacteria. We clearly show that this adaptation can lead to a considerable gain in efficacy, as mortality decreased from 80% to 25% when using an adapted bacteriophage. The adaptation procedure used was based on evolution of population where the most efficient bacteriophages are favored. After each passage, during which 536_P7 bacteriophage was infecting strain PDP302, a fraction of the evolved viral population was submitted to the next round. After five rounds, bacteriophages from a plaque-forming unit were amplified and purified to establish the adapted 536_P7_PDP302 bacteriophage population.
Previous studies focusing on bacteria-bacteriophages interactions have already described several mechanisms by which bacteriophages may improve their infectivity. These include increase in adsorption capability achieved by receptor variation (39) (40) (41) (42) , increase in number of released viruses (43) , shortening of latent period, and improvement of resistance to bacterial defense against virus invasion using anti-clustered regularly interspaced short palindromic repeats system (44, 45) . It should also be noted that the adaptation procedure performed in vitro is not an absolute guarantee to drive the selection of a bacteriophage variant toward in vivo improved efficacy (37) .
This study has some potential limitations. First, one could argue that treatment with bacteriophages was administered shortly after bacterial challenge (2 hr). This delay is within the same order of magnitude than that of other models of acute infection with different pathogens (mainly E. coli, Streptococcus pneumonia, and Klebsiella pneumoniae), varying between 1 and 4 hours (46) (47) (48) (49) . This takes into account the fact that, contrary to the clinical scenario, pneumonia develops within hours of a large and single bacterial inoculation, as demonstrated by the kinetic of the bioluminescence signal. We, however, cannot rule out that a delayed treatment (bacteriophage and antibiotic based) could be less efficient.
Second, some could question the applicability of phage therapy to the ICU because of time constraints to obtain a specific bacteriophage against the identified bacteria. There are in fact two arguments that on the contrary support the use of bacteriophages in ICU: 1) based on the epidemiological surveillance of clinical strains sampled over the years in hospitals, it is possible to elaborate cocktails of several ready-to-use bacteriophages, thereby extending host spectrum (50), and 2) most importantly, because oropharyngeal colonization precedes nosocomial pneumonia (51), it will be possible right from the beginning to select bacteriophages against the bacteria (eventually including an adaptation step as described in our study) and have the treatment available when the infection occurs. Finally, administering bacteriophages once colonization is detected may be a means to prevent secondary infection. Third, caution is required regarding the extrapolation of our experimental results to the clinical setting of mechanical ventilation. Obviously, they serve as a proof of concept and whether similar results will be obtained in mechanically ventilated lungs, within pre-existing inflammation and possible injury, will need to be addressed in future studies.
Finally, a possible toxicity related to bacteriophage therapy can be questioned. First of all, it is important to recall that bacteriophages are not foreign to the human being, since we harbor a vast amount of bacteriophages, mainly in our intestinal tract and mucous membranes (52) . We also eat and drink each day thousands of bacteriophages without experiencing any trouble (53) . Second, contrary to viruses used in viral gene therapy, bacteriophages are unable to penetrate eukaryotic cells. Third, from an immunological point of view, bacteriophages do not elicit a significant acute inflammatory response in mammals as shown by several studies on both purified structural proteins and entire virions (17, 54) . In our work, we observed a nonsignificant increase in BAL fluid total proteins in bacteriophage-treated mice compared with control mice 6 hours post infection (208 and 140 μg/mL, respectively). Importantly, this difference was not confirmed at H16 (304 and 320 μg/mL, respectively) while the amount of bacteriophages increased (Table 1 ). We therefore believe that these nonsignificant differences reflect sampling fluctuation rather than differences in lung permeability (in addition, LDH activity is identical in both group at H6 and tends to be weaker in bacteriophage-treated mice at H16). This absence of acute immunological response should be distinguished from the long-lasting humoral immunity where, conversely, bacteriophages have been shown to be able to induce specific antibodies production (55) . Although not harmful for the host, these antibodies could be problematic if a repeated administration of the bacteriophage is planned because these antibodies could be neutralizing.
Many reviews have listed pros and cons of phage therapy (56) , which is beyond the scope of this work. We can, however, mention that bacteriophages reported here fit well into a consensus, which indicates that all candidate bacteriophages should be sequenced (in order to discard those which carry putative unwelcome genes, mainly toxins and antibiotic-resistance genes) and when possible, the most infective bacteriophages (based on in vitro assessment) should be chosen.
Facing growing bacterial resistance to antibiotics, urgent measures need to be taken both to spare antibiotics and to investigate new therapeutic strategies. Among putative solutions, use of bacteriophages is the only one to have been widely used in the past in humans (57) . Regarding lung infection, bacteriophage treatment of experimental P. aeruginosa pneumonia with strains isolated in cystic fibrosis patients or Klebsiella infection also proven to be effective (18, 20, 37, 58, 59) . For all of the above reasons and because patients in the ICU are among the most exposed to the threat of resistant pathogens (and therefore under close bacterial surveillance), the ICU setting seems to be particularly appropriate for phage therapy to fight bacterial infections. This is in agreement with recent calls to promote the use of phage therapy to overcome antibioresistance, to limit antibiotic selective pressure, and to protect natural commensals (14) (15) (16) . Our results provide then the first evidence that bacteriophage therapy could be part of the nosocomial pneumonia treatment.
